Stroke worry and QoL issues sway US panel against Abiomed's artificial heart
This article was originally published in Clinica
The introduction in the US of a total artificial heart (TAH) as a last-ditch treatment for the most sick cardiac patients needs to be put on hold until various safety questions are answered, a deeply divided FDA advisory committee on June 23.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.